x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231287
| Product Information | |
|---|---|
| CAS No. | 467214-21-7 |
| Synonyms | 17-DMAG, KOS-1022, NSC707545, 17-demethoxy-17-[[2-(dimethylamino)ethyl]amino]-geldanamycin |
| Formula | C32H48N4O8 • HCl |
| Molecular Weight | 653.2 |
| Target | HSP90 |
| Product Description | Alvespimycin HCl, also known as 17-DMAG, is a potent, water-soluble HSP90 inhibitor. Alvespimycin has diverse anti-tumor actions and has potential in treating a number of different types of cancers, including ovarian, prostate, melatnoma, non-small-cell lung cancer, and several leukemias (chronic lymphocytic, acute myeloid). This compound also suppresses inflammation by interfering with signaling through the NF-κB pathway. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 95% |
| Shipping | Shipped at room temperature. |
| Storage | Store at or below –20 °C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day. |
| Solubility Overview | Soluble in DMSO (100 mM). Solubility in water is less than 1 mg/mL (1 mM). |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
